Enzyme-armored CAR-T Development Service for Solid Tumor Targeting

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs' Enzyme-Armored CAR-T Development Service for Solid Tumor Targeting is designed to overcome poor T-cell infiltration, immunosuppressive microenvironments, and limited persistence in solid tumors. By integrating advanced enzyme engineering with optimized T-cell modification platforms, CAR-T cells are equipped with targeted enzymatic payloads that remodel the tumor extracellular matrix and stromal barriers. This approach enhances tumor penetration, boosts local anti-tumor activity, and strengthens overall efficacy, enabling researchers to develop more potent and resilient CAR-T strategies for difficult-to-treat solid tumor indications.

Introduction

Enzyme-armored CAR-T cells integrate extracellular matrix (ECM)-degrading enzymes to overcome the dense stromal and matrix barriers characteristic of solid tumors. Published research demonstrates that hyaluronidase or heparinase-modified CAR-T cells show improved infiltration and enhanced tumor clearance, supporting their potential as next-generation solid tumor immunotherapies.

Various components of the tumor microenvironment. (OA Literature) Fig.1 Diverse elements of the tumor microenvironment.¹

Enzyme-armored CAR-T Development at Creative Biolabs

Creative Biolabs offers a powerful solution to the primary barriers limiting CAR-T efficacy in solid tumors—namely, the dense ECM and the subsequent restricted T-cell trafficking. By integrating an enzyme (such as Heparanase or Hyaluronidase) directly onto or into the CAR-T cell, we provide a self-contained, tumor-targeting demolition unit. This approach enables the armed T cells to actively degrade key ECM components like heparan sulfate proteoglycans or hyaluronic acid, clearing a path for deep and broad infiltration into the solid tumor mass.

Our specific deliverables include the selection and validation of the ideal enzyme for your target tumor type, the design and optimization of the co-expression construct, and the generation of a highly potent, armed CAR-T product ready for pre-clinical evaluation. This systematic approach results in CAR-T cells that demonstrate superior anti-tumor activity and greater longevity in challenging TME settings compared to conventional designs.

Discover How We Can Help - Request a Consultation.

Enzyme-Based Module Strategy

Membrane-anchored ECMase

Membrane-anchored ECM-degrading enzymes are localized on the CAR-T cell surface to selectively degrade surrounding tumor ECM components. This strategy locally clears the tumor barrier, enhancing CAR-T infiltration while minimizing off-target damage, offering a high safety profile.

Secretion-Tunable ECMase

Secretion-tunable enzymes are released by CAR-T cells to reduce tumor ECM viscosity and interstitial pressure. By integrating tumor microenvironment-specific signals or control switches, enzyme activity is restricted to the tumor site, improving infiltration and cytotoxicity while minimizing systemic toxicity and off-tumor effects.

CAF-Targeted Dual CAR

Dual-targeted CARs recognize both tumor cells and cancer-associated fibroblasts (CAF). This approach simultaneously diminishes the tumor and ECM-derived barriers, enhancing CAR-T penetration into solid tumors and reshaping the tumor microenvironment to support sustained immune cell infiltration and tumor killing.

Protease-Activatable CAR

Protease-activatable CARs incorporate tumor-specific MMP-cleavable linkers, activating CAR function only in ECM-dense tumor environments. This design confines CAR-T activity to the tumor, reducing toxicity and off-tumor responses while maintaining potent anti-tumor efficacy, offering precise control and improved safety for solid tumor therapy.

Project Workflow

Workflow of Enzyme-armored CAR-T Development. (Creative Biolabs Original)

The final deliverables include the engineered enzyme-armed CAR-T cell product, a comprehensive QC and release data report, and a detailed in vivo efficacy report with tumor volume and survival data.

Unique Features

End-to-end enzyme-armored CAR-T development: from antigen and enzyme selection to in vitro and in vivo validation.
Custom CAR construct engineering with precise enzyme expression control (constitutive, inducible, or tumor-responsive).
Standardized quality control checkpoints for phenotype stability, enzymatic function, and cytotoxic performance.
Comprehensive documentation packages supporting technology transfer, collaboration, and preclinical development planning.

FAQs

Can enzyme-armored CAR-T cells be tuned to avoid excessive ECM degradation?

Yes. Expression can be controlled by inducible promoters, protease-cleavable secretion signals, or tumor-selective regulatory elements to localize enzyme activity. We tailor this design depending on your safety and translational considerations.

How do enzyme-armored CAR-T cells compare to chemokine receptor-enhanced CAR-T cells?

Chemokine receptor engineering improves directional homing, while enzyme-armoring improves physical tumor penetration. These two approaches are complementary, and many clients pursue a combined design to maximize infiltrative efficiency. We can help you assess whether a dual strategy is beneficial.

What sample materials or data do I need to provide to begin a project?

Typically, we recommend providing target antigen information, preferred CAR format or scFv, and tumor model or cell line profiles. If needed, we can also assist with tumor profiling and model selection.

Partner with Us

Creative Biolabs provides a comprehensive Enzyme-armored CAR-T Development Service for Solid Tumor Targeting, enabling research teams and therapeutic developers to overcome the physical extracellular matrix barriers that limit CAR-T performance in solid tumors. Through custom enzyme selection, precise expression control, advanced in vitro and in vivo validation, scalable production workflows, and rigorous quality analytics, we support projects from early feasibility through preclinical advancement.

Our scientific team is available to discuss your research goals, technical requirements, and potential development strategies. We welcome inquiries from academic groups, biotech innovators, and industry partners. Connect with us to review customized safety measures.

Reference

Kuznetsova, A V et al. "NK cell activity in the tumor microenvironment." Frontiers in cell and developmental biology vol. 13 1609479. 30 May. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fcell.2025.1609479

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.